WORCESTER, Mass., Aug. 5, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has received approval from the ethics committee at University Campus Bio-Medico of Rome to conduct a Generex Oral-lyn trial with subjects diagnosed with or susceptible to developing Impaired Glucose Tolerance (IGT). The endpoint of the study is to determine if glucose levels will drop when subjects use Generex Oral-lyn, the Company’s proprietary oral insulin spray product, with the Company’s proprietary RapidMist(tm) drug delivery device.
